Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
RAD51 与同源重组缺陷 (HRD) 及未经治疗的三阴性乳腺癌 (TNBC) 临床结果的关联：GeparSixto 随机临床试验分析
期刊:Annals of Oncology
影响因子:56.7
doi:10.1016/j.annonc.2021.09.003
A Llop-Guevara, S Loibl, G Villacampa, V Vladimirova, A Schneeweiss, T Karn, D-M Zahm, A Herencia-Ropero, P Jank, M van Mackelenbergh, P A Fasching, F Marmé, E Stickeler, C Schem, R Dienstmann, S Florian, V Nekljudova, J Balmaña, E Hahnen, C Denkert, V Serra
